Trial · NCT04477590
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Insulin sensitivity assessed using intravenous glucose tolerance test | 12 months | Curves of insulin-mediated glucose clearance, inhibition of lipolysis, and liver glucose output measured with the use of stable isotope infusion. |
| Primary | Post-prandial lipemia assessed by an oral fat tolerance test | 12 months | Rates of appearance and clearance of liver VLDL-TG, Apolipoprotein B, and fatty acids using stable isotopes. |
| Primary | Blood pressure assessed by ECG-gated automated sphygmomanometer | 12 months | Determined immediately after treatments and during the following 24-h using ambulatory blood pressure Holter-type monitors. |
| Primary | Glycemic control assessed by 24-h continuous interstitial glucose monitoring | 36 months | Determined by a patch glucose sensor paired with a glucose monitor. |
| Secondary | Body composition. | 12 months | Determined by bioelectrical impedance to calculate body fat mass and fat free mass. |
| Secondary | Body mass index | 12 months | Determined by body weight (kg) and height (m) to calculate body mass index (kg/m2) |
| Secondary | Maximal oxygen consumption during a graded exercise test to exhaustion, assessed by indirect calorimetry | 12 months | Calculation of cardiorespitarory fitness |
| Secondary | Resting metabolic rate assessed by indirect calorimetry while lying after an overnight fast | 12 months | Using indirect calorimetry and a ventilated canopy system |
| Secondary | Maximal rate of fat oxidation assessed by indirect calorimetry during a submaximal exercise test. | 12 months | Calculated in grams per min during the incremental cycle ergometer test with the use of indirect calorimetry system |
| Secondary | 24-hour monitoring of blood concentrations of metformin, statins, and angiotensin blockers assessed using gas chromatography-mass spectrometry. | 36 months | To study the pharmacokinetics of the habitual medicines used by our subjects during the different experimental conditions |
| Secondary | The activity of intramuscular proteins (enzymes) involved in energetics assessed using western blots. | 36 months | Measured in skeletal muscle obtained by percutaneous muscle biopsy. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04477590/registered